Impact of progesterone receptor semiquantitative immunohistochemical result on oncotype DX recurrence score: A quality assurance study of 1074 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 4, 2013, Pages 287-291

  Clark, Beth Z ^a   Dabbs, David J ^a   Cooper, Kristine L ^b   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

breast cancer; Oncotype DX; progesterone receptor; semiquantitative immunohistochemical H score; tumor grade

Indexed keywords

PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NOTTINGHAM GRADING SYSTEM; ONCOTYPE DX RECURRENCE SCORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR INVASION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880920579     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31826f80c9     Document Type: Article

References (22)

1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24:3726-3734.
3. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255-1261.
4. Allison KH, Kandalaft PL, Sitlani CM, et al. Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: Who does not always need testing? Breast Cancer Res Treat. 2012;131:413-424.
5. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med. 2010;134:1697-1701.
6. Tang P, Wang J, Hicks DG, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010;28: 978-982.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
8. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev. 1995;4:319-326.
9. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97:1254-1261.
10. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979.
11. Balleine RL, Earl MJ, Greenberg ML, et al. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer. 1999;79:1564-1571.
12. Moon YW, Park S, Sohn JH, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptorpositive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137:1123-1130.
13. Albert JM, Gonzalez-Angulo AM, Guray M, et al. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011;117:1595-1601.
14. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol. 2005;23: 7512-7517.
15. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059-1065.
16. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res. 2001;7:4436s-4442s; discussion 4411s-4412s.
17. Arteaga CL. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19:32S-40S.
18. Giuliano M, Schifp R, Osborne CK, et al. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011;20(suppl 3):S42-S49.
19. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926-935.
20. Tomlinson IP, Nicolai H, Solomon E, et al. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol. 1996;180:38-43.
21. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res. 1995;55:2660-2664.
22. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273-4278.